Your Messages Inbox
Your Article Summary
See Latest ArticlesOnyx Pharmaceuticals Announces A Teleconference And Webcast To Provide An Update On Nexavar
Onyx Pharmaceuticals, 04/28/09
Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer by changing the way cancer is treated. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar, a small molecule drug. Nexavar is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in non-small cell lung cancer, melanoma, breast cancer, and other cancers.
Today in Conferences/Meetings...keeping you current
Receive free subspecialty "5-minute updates" via email
Repligen Announces Conference Call to Discuss Phase 3 Clinical Trial Results of RG1068 in MRI Imaging of the Pancreas Wednesday, December 9
Repligen, 12/09/09
Allos Therapeutics' FOLOTYN Demonstrates Activity in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma Treated with Stem Cell Transplant
Allos Therapeutics, 12/08/09
ARIAD Presents Positive Clinical Proof-of-Concept Data on AP24534 in Drug-Resistant Hematological Cancers at ASH Annual Meeting
ARIAD Pharmaceuticals, 12/08/09
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Recombinant Human Erythropoietin, Epogin Injection
Application for Approval of Additional Indication of Chemotherapy-Induced Anemia
Chugai Pharmaceutical Co., 12/08/09
Synthon announces European approvals for Raloxifene
Synthon, 12/08/09
US FDA approves SEROQUEL for the pediatric treatment of schizophrenia and bipolar mania
AstraZeneca, 12/07/09
Article Search
Sponsor